Want to see VIR full AI Analyst Report?
VIR Stock Chart & Stats
$10.75
$5.76(73.00%)
At close: 4:00 PM EST
$10.75
$5.76(73.00%)
Day’s Range― - ―
52-Week Range$4.16 - $11.66
Previous CloseN/A
Volume25.73M
Average Volume (3M)1.92M
Market Cap
$1.54B
Enterprise Value$1.39B
Total Cash (Recent Filing)$472.36M
Total Debt (Recent Filing)$95.58M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Jul 30, 2026EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.13
Shares Outstanding168,651,980
10 Day Avg. Volume2,314,431
30 Day Avg. Volume1,916,741
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.09
Price to Sales (P/S)12.18
P/FCF Ratio-2.11
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue21.19
Enterprise Value/Gross Profit7.70
Enterprise Value/Ebitda-3.17
Forecast
1Y Price Target
$21.43Price Target Upside99.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.93
Revenue Forecast (FY)$161.89M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Extended RunwaySubstantial cash reserves and recent financing materially reduce near-term dilution and financing risk, enabling the company to fund pivotal HDV and VIR‑5500 studies and commercial prep. Low leverage adds flexibility, supporting sustained R&D execution and partnership obligations over the next 2–3 years.
Astellas Global Collaboration For VIR‑5500A large strategic licensing deal validates VIR‑5500, shares development/commercial costs and accelerates global access. Milestones and profit‑share economics provide contingent capital and decrease single‑company commercialization risk, strengthening long‑term program viability and strategic optionality.
Compelling HDV Data And Regulatory DesignationsRobust SOLSTICE efficacy signals plus multiple regulatory expedited designations improve the probability and speed of approval. Ongoing registrational ECLIPSE trials create a clear regulatory pathway and durable value creation potential by converting clinical progress into marketable therapies if enrollment and endpoints hold.
Bears Say
Collapsed Revenue Base And Persistent Cash BurnThe company lacks stable product revenue and remains heavily loss‑making, with free cash flow closely tracking large net losses. This structural cash burn requires continued external funding or milestone receipts to sustain operations, raising dilution and execution risk if clinical or partner milestones are delayed.
Approval Requires Multiple Pivotal DatasetsA regulatory pathway that depends on multiple trials extends timelines and multiplies execution risks and costs. Needing combined datasets increases capital needs, delays potential revenue, and magnifies dependency on consistent trial enrollment, endpoint achievement, and regulatory alignment across studies.
Class‑level And Program Safety Risks For T Cell EngagersSafety signals in the masked T cell engager class create persistent regulatory and development risk. Even with PROXTEN masking, novel or class toxicities could force trial modifications, slow enrollment, or require additional studies, increasing costs and jeopardizing approval or commercial adoption timelines.
Vir Biotechnology News
VIR FAQ
What was Vir Biotechnology, Inc.’s price range in the past 12 months?
Vir Biotechnology, Inc. lowest stock price was $4.16 and its highest was $11.66 in the past 12 months.
What is Vir Biotechnology, Inc.’s market cap?
Vir Biotechnology, Inc.’s market cap is $1.54B.
When is Vir Biotechnology, Inc.’s upcoming earnings report date?
Vir Biotechnology, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 26 days.
How were Vir Biotechnology, Inc.’s earnings last quarter?
Vir Biotechnology, Inc. released its earnings results on May 06, 2026. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.096 by -$0.754.
Is Vir Biotechnology, Inc. overvalued?
According to Wall Street analysts Vir Biotechnology, Inc.’s price is currently Undervalued.
Does Vir Biotechnology, Inc. pay dividends?
Vir Biotechnology, Inc. does not currently pay dividends.
What is Vir Biotechnology, Inc.’s EPS estimate?
Vir Biotechnology, Inc.’s EPS estimate is 0.33.
How many shares outstanding does Vir Biotechnology, Inc. have?
Vir Biotechnology, Inc. has 168,651,980 shares outstanding.
What happened to Vir Biotechnology, Inc.’s price movement after its last earnings report?
Vir Biotechnology, Inc. reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.096. Following the earnings report the stock price went down -9.913%.
Which hedge fund is a major shareholder of Vir Biotechnology, Inc.?
Currently, no hedge funds are holding shares in VIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vir Biotechnology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.43 (99.34% Upside)
$21.43 (99.34% Upside)
Blogger Sentiment
Bullish
VIR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 48.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.89%
12-Months-Change
Fundamentals
Return on Equity
-53.31%
Trailing 12-Months
Asset Growth
-21.57%
Trailing 12-Months
Company Description
Vir Biotechnology, Inc.
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
VIR Company Deck
VIR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum: a large strategic collaboration with Astellas closed with immediate and near-term cash, meaningful capital raises, strong Phase 1 safety/early efficacy for VIR-5500, and highly differentiated Phase 2 HDV data with regulatory support and multiple registrational trials underway. Offsetting these positives are continued quarterly net losses, high R&D spend, the need for multiple pivotal datasets for filing in HDV, underdiagnosis in the target HDV population, and class-level safety/competitive risks for T cell engagers. On balance, the advances in clinical data, strategic partnerships, and strengthened balance sheet materially outweigh the near-term financial and execution risks.View all VIR earnings summariesVIR Stock 12 Month Forecast
Average Price Target
$21.43
▲(99.34% Upside)
Technical Analysis
Ownership Overview
10.11% Insiders
13.87% Mutual Funds
0.01% Other Institutional Investors
53.30% Public Companies and
Individual Investors